FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPRO	JVAL				
OMB Number:	3235-0287				
Estimated average bur	den				
hours per response:	0.5				

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1(c). S	ee Instruction 1	0.											_						
Name and Address of Reporting Person* Thompson Peter A.					2. Issuer Name and Ticker or Trading Symbol ARS Pharmaceuticals, Inc. [SPRY]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner					
(Last) C/O ARS		3. Date of Earliest Transaction (Month/Day/Year) 08/21/2024									Officer (give title Other (specify below) below)								
11682 EL CAMINO REAL, SUITE 120					4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) SAN DIEGO CA 92130															filed by		oorting Pe an One Re		
(City)	(St	ate) (Z	Zip)																
		Table	I - Non-Deriva	ative	e Secu	rities	Acqu	uire	ed, D	isposed	of, or	Benefi	cia	ally Own	ed				
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)				2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		tion I	4. Securities A Disposed Of		quired (A) or (Instr. 3, 4 and 5)		5. Amount of Securities Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)		
							Code	вΙ	v /	Amount	(A) or (D)	Price		Reported Transactio (Instr. 3 an				,	
Common	08/21/2024	-			S			394,400	D	\$13.52	(1)	557,9	77	I	Se Fo	e ootnote ⁽⁵⁾⁽⁸⁾			
Common	08/21/2024	ļ			S			13,300	D	D \$14.61		544,677		I	Se Fe	e ootnote ⁽⁵⁾⁽⁸⁾			
Common Stock 08/22/							S			391,482	D	\$12.94	(3)	153,1	95	I	Se Fe	e ootnote ⁽⁵⁾⁽⁸⁾	
Common Stock 08/23/2024				!			S			69,500	D	\$13.03	(4)	83,69	95	I	Se Fo	e ootnote ⁽⁵⁾⁽⁸⁾	
Common Stock														269,3	23	I	Se Fo	e ootnote ⁽⁶⁾⁽⁸⁾	
Common Stock														8,019,	187	I	Se Fo	e ootnote ⁽⁷⁾⁽⁸⁾	
		Tal	ole II - Derivat (e.g., pu							sposed o					d				
1. Title of Derivative Security (Instr. 3)	Derivative Conversion Date Execution Descurity or Exercise (Month/Day/Year) if any			4. Transaction Code (Instr. 8)		5. Nu of Deriv	mber rative rities ired r osed)	6. Date Exercisable and Expiration Date			d 7. T Am Sec Und Der Sec	ritle and ount of curities derlying rivative curity (Inst and 4)	8. Price of Derivative Security (Instr. 5)				10. Ownershi Form: Direct (D) or Indirec (I) (Instr. 4	Beneficial Ownership t (Instr. 4)	
				Cod	le V	(A)		Date Exe	e rcisab	Expiration	on Titl	Amour or Number of Shares	er						

Explanation of Responses:

- 1. Represents the weighted average sale price of the shares of the Issuer's common stock sold, ranging from a low of \$13.30 to a high of \$13.925 per share. The Reporting Person undertakes, upon request by the staff of the Securities and Exchange Commission, the Issuer or a securityholder of the Issuer, to provide full information regarding the number of shares sold at each separate price.
- 2. Represents the weighted average sale price of the Issuer's common stock sold, ranging from a low of \$14.605 to a high of \$14.615 per share. The Reporting Person undertakes, upon request by the staff of the Securities and Exchange Commission, the Issuer or a securityholder of the Issuer, to provide full information regarding the number of shares sold at each separate price
- 3. Represents the weighted average sale price of the shares of the Issuer's common stock sold, ranging from a low of \$12.765 to a high of \$13.475 per share. The Reporting Person undertakes, upon request by the staff of the Securities and Exchange Commission, the Issuer or a securityholder of the Issuer, to provide full information regarding the number of shares sold at each separate price
- 4. Represents the weighted average sale price of the shares of the Issuer's common stock sold, ranging from a low of \$12.80 to a high of \$13.20 per share. The Reporting Person undertakes, upon request
- by the staff of the Securities and Exchange Commission, the Issuer or a securityholder of the Issuer, to provide full information regarding the number of shares sold at each separate price. 5. These securities are held of record by OrbiMed Partners Master Fund Limited ("OPM"). OrbiMed Capital LLC ("OrbiMed Capital") is the investment advisor to OPM. OrbiMed Capital is a relying
- advisor of OrbiMed Advisors LLC ("OrbiMed Advisors"). OrbiMed Advisors and OrbiMed Capital exercise voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPM. 6. These securities are held of record by OPI VI - IP HoldCo LLC ("HoldCo"). OrbiMed Capital GP VI LLC ("GP VI") is the sole member of OrbiMed Private Investments VI - IP, LP, which is the sole
- member of OPI VI IP TopCo LLC, the sole member of HoldCo. OrbiMed Advisors is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by HoldCo and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by HoldCo. 7. These securities are held of record by OrbiMed Private Investments VI, LP ("OPI VI"), GP VI is the general partner of OPI VI, and OrbiMed Advisors is the managing member of GP VI. By virtue of

such relationships, GP VI and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VI and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VI.

8. Each of the Reporting Person, OrbiMed Advisors, GP VI, and OrbiMed Capital disclaim beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP VI, or OrbiMed Capital is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.

<u>/s/ Peter A. Thompson</u> <u>08/23/2024</u>

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.